Logo Skip to main content
  • Our Company
    • About Us
    • Leadership Team
  • Our Science
    • cGAS-STING Pathway
    • Therapeutic Applications
    • Partnership Opportunities
    • Clinical Trials
    • Publications
    • Presentations
  • Pipeline
    • Our Pipeline
    • IMSB301 cGAS Inhibitors
  • News
    • Press Releases
    • Events
    • In the News
  • Careers
  • Contact Us

Our Science

Latest Presentations

2024

Phase 2 Clinical Trials to Evaluate the Safety and Efficacy of IMSA101 STING Agonist in Combination with Radiotherapy and Checkpoint Inhibitors in Oligometastatic (OMD) and Oligoprogressive (OPD) Solid Tumors.
2024 ASCO Annual Meeting.

  • Home
  • Our Company
    • About Us
    • Leadership Team
  • Our Science
    • cGAS-STING Pathway
    • Therapeutic Applications
    • Partnership Opportunities
    • Clinical Trials
    • Publications
    • Presentations
  • Pipeline
    • Our Pipeline
    • IMSB301 cGAS Inhibitors
  • News
    • Press Releases
    • Events
    • In the News
  • Careers
  • Contact Us
ImmmuneSensor Therapeutics Logo

ImmuneSensor Therapeutics
2110 Research Row, Suite 610
Dallas, TX 75235

info@immunesensor.com

  • Privacy Policy
  • Terms & Conditions
© 2025 ImmmuneSensor Therapeutics All rights reserved.